Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials

Very short duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) has recently attracted a lot of attention with the introduction of newer generations stents. This is appealing, especially in patients at high bleeding risk. However, none of the trials were po...

Descripción completa

Detalles Bibliográficos
Autores principales: Parfrey, Shane, Abdelrahman, Amr, Blackman, Daniel, Blaxill, Jonathan M., Cunnington, Michael S., Greenwood, John P., Malkin, Christopher J., Mozid, Abdul M., Rossington, Jennifer A., Veerasamy, Murugapathy, Wassef, Nancy, Wheatcroft, Stephen B., Bulluck, Heerajnarain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615356/
https://www.ncbi.nlm.nih.gov/pubmed/36307769
http://dx.doi.org/10.1186/s12872-022-02900-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615356/
https://www.ncbi.nlm.nih.gov/pubmed/36307769
http://dx.doi.org/10.1186/s12872-022-02900-6

Ejemplares similares